Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Trial Profile

A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Paclitaxel (Primary) ; Phenelzine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms Epi-PRIMED
  • Sponsors EpiAxis Therapeutics
  • Most Recent Events

    • 01 Dec 2018 According to an EpiAxis Therapeutics media release, the company has expanded this study by including two additional recruitment centres. The two new centers are the Southern Medical Day Care Centre in Wollongong and at the Liverpool Cancer Therapy Centre. The principle investigators at these centre are Professor Phil Clingan and Dr Eugene Moylan, respectively.
    • 14 Nov 2018 New trial record
    • 08 Nov 2018 Recruitment completion is expected on 24 June 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top